decisionhealth Newsletters, Part B News - 2020 Issue 11 (November)
COVID vaccine, therapeutics rule issued
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an HHS interim final rule issued with a request for comments and explains its broad impact on COVID-19 vaccine coverage and payment policy. It is relevant to health care payers, hospitals, Medicare-related billing staff, and coding/compliance professionals who track federal rules affecting preventive services and reimbursement for emerging COVID-19 therapies.
Why This Topic Matters
Federal coverage and payment rules can affect payer policy, provider enrollment, and reimbursement workflows across multiple health care settings. Understanding the scope of this rule helps organizations monitor changes involving COVID-19 preventive services and related therapeutic payment policy.
What You Will Learn
- The federal agencies involved in issuing the interim final rule
- The general coverage and payment policy areas addressed by the rule
- How the rule relates to Medicare preventive service coverage and provider enrollment
- The broader reimbursement context for COVID-19 therapeutics and hospital payment adjustments
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Revenue cycle teams
- Hospital administrators
- Health plan staff
- Medicare providers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com